BNC KOREA (A256840) Stock Overview
Engages in the research and development, production, and sale of biomaterials for medicines in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Risk Analysis
No risks detected for A256840 from our risk checks.
A256840 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BNC KOREA, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,980.00 |
| 52 Week High | ₩6,180.00 |
| 52 Week Low | ₩2,905.00 |
| Beta | 0.50 |
| 1 Month Change | -23.49% |
| 3 Month Change | -26.60% |
| 1 Year Change | -41.80% |
| 3 Year Change | -23.59% |
| 5 Year Change | -62.52% |
| Change since IPO | 51.27% |
Recent News & Updates
BNC Korea's (KOSDAQ:256840) Sluggish Earnings Might Be Just The Beginning Of Its Problems
A lackluster earnings announcement from BNC Korea Co., Ltd. ( KOSDAQ:256840 ) last week didn't sink the stock price...Subdued Growth No Barrier To BNC Korea Co., Ltd.'s (KOSDAQ:256840) Price
BNC Korea Co., Ltd.'s ( KOSDAQ:256840 ) price-to-earnings (or "P/E") ratio of 23.4x might make it look like a strong...Recent updates
Shareholder Returns
| A256840 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.8% | -7.9% | -3.8% |
| 1Y | -41.8% | 15.1% | 173.0% |
Return vs Industry: A256840 underperformed the KR Biotechs industry which returned 19.7% over the past year.
Return vs Market: A256840 underperformed the KR Market which returned 188.8% over the past year.
Price Volatility
| A256840 volatility | |
|---|---|
| A256840 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in KR Market | 15.8% |
| 10% least volatile stocks in KR Market | 4.3% |
Stable Share Price: A256840 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A256840's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 250 | Wan-Gyu Choi | www.bnckorea.co.kr |
BNC KOREA, Inc. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia.
BNC KOREA, Inc. Fundamentals Summary
| A256840 fundamental statistics | |
|---|---|
| Market cap | ₩203.82b |
| Earnings (TTM) | -₩3.25b |
| Revenue (TTM) | ₩91.21b |
Is A256840 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A256840 income statement (TTM) | |
|---|---|
| Revenue | ₩91.21b |
| Cost of Revenue | ₩56.69b |
| Gross Profit | ₩34.52b |
| Other Expenses | ₩37.78b |
| Earnings | -₩3.25b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -47.56 |
| Gross Margin | 37.85% |
| Net Profit Margin | -3.57% |
| Debt/Equity Ratio | 10.8% |
How did A256840 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/05 04:51 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BNC KOREA, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kwan Jun Ra | NH Investment & Securities Co., Ltd. |